Clinical Trials Directory

Trials / Completed

CompletedNCT04874324

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Oral WCK 2349

Phase-I Double-blind, Randomized, Placebo-controlled Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Oral WCK 2349 Under Fasting Conditions in Adult Healthy Human Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Wockhardt · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The present study is planned to assess the safety, tolerability and pharmacokinetic profile of WCK 2349 in US subjects with selected ascending multiple doses of WCK 2349 and to compare the safety, tolerability and pharmacokinetic data with the data observed in similar studies conducted in India.

Conditions

Interventions

TypeNameDescription
DRUGWCK 2349 Oral1 dose given orally twice daily at 12 hourly interval for five days.
OTHERPlacebo OralSubjects will receive matching placebo

Timeline

Start date
2011-03-17
Primary completion
2011-05-04
Completion
2011-06-25
First posted
2021-05-05
Last updated
2022-12-01

Regulatory

Source: ClinicalTrials.gov record NCT04874324. Inclusion in this directory is not an endorsement.

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Oral WCK 2349 (NCT04874324) · Clinical Trials Directory